APAC
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma APAC – English USA – English USA – English Japan – Japanese Korea – 한국어 USA – español USA – Deutsch
December 22, 2024 | by Admin Editor